New post on FCPA Compliance and Ethics Blog

Telling the Board what it needs to know Regarding Compliance – The Pfizer Experience (Originalwiedergabe des Blogartikels) . Wichtige Lektion: Compliance Abteilung und Rechtsabteilung getrennt halten.

An article in the July Issue of Compliance Week Magazine, entitled “Telling Your Board What it Needs to Hear”, author Arielle Bikard discusses the views of Pfizer Inc’s Chief Compliance Officer (CCO), Douglas Lankler, on how he keeps the Pfizer Board of Directors up to date on compliance issues. There are many articles which focus on the information that a Board of Directors may want to receive and this is one of the few articles which focuses on the issues from the perspective of the CCO.

Reporting Structure. Due to a recent compliance enforcement action, Pfizer was forced to separate its compliance function from its legal function and Lankler began to report directly to the Board. This has led to a tripartite level of reporting at the Board level. There is a monthly meeting of the Audit Committee, to which he reports to, by telephone and bi-monthly in person meetings, to which Lankler also reports. There is also a special Board level committee dedicated to regulatory and compliance issues, to which Lankler began reporting to in June. Lankler also submits an annual report to the full Board.

What is Measured and How is it Presented

Lankler noted that the Pfizer Board is “very concerned about how the company is measuring improvements in the compliance function.” To provide this information, Lankler measures the results of inspections during internal monitoring and auditing. He provided the example of whether a country assessed received a “generally satisfactory” rating as opposed to the lessor rating of ‘satisfactory”. He is also measured on “how much bad stuff I prevent from happening.” To determine this metric, Lankler brings in “external environmental considerations” which look at what is happening in the industry and what his and Pfizer’s peers may be facing from the compliance perspective.

Lankler believes that the key to reporting is to provide sufficient information presented in a manner which puts the emphasis on what is important. To achieve the latter, he prepares a tracking chart and uses a red, yellow and green dot next to each line of information. He believes that this allows the conversation with the Board to be directed “in a way that makes sense.” If he adds to or subtracts from the tracking chart, “the change and its cause are highlighted in a memo to the Board.”

The annual report which is submitted to the Board comes in at 30 pages or so. In it, Lankler sets out four different areas which he beli…

» Vollständiger Artikel
  • Infos zum Artikel
  • Kommentare
  • Ähnliches

Themen: Pfizer , Ethics , Fcpa , Annual Report , Board OF Directors

Erschienen 13. Oktober 2011 auf http://www.usa-recht.de.

Sie haben eine Meinung zum Thema? Artikels kommentieren
Artikel kommentieren

FCPA: Boards of Directors and Compliance: Four Areas of Inquiry

USA Recht | 20. Februar 2012 — In an article in the December 2011 issue of Compliance Week Magazine, entitled “Board Checklist: What Every Director Should Kno…

Three Keys to the Role of a Chief Compliance Officer

USA Recht | 7. April 2012 — There is an ongoing debate in the compliance world about whether a company can or should combine or separate the role of the …

FCPA: The Saga of MF Global – Don’t Shoot the Messenger, Fire the Chief Compliance Officer

USA Recht | 27. Februar 2012 — In a post last week on his site, Corruption, Crime and Compliance, Mike Volkov named the Chief Compliance Officer (CCO) his “…

Forreign Corrupt Practices Act – Best Practices

USA Recht | 13. Dezember 2010 — Nachfolgende dreizehn Punkte sind Punkte, die in den letzten FCPA Verfahren des Department of Justice und der Securities and …

FCPA: Marc Anthony Redux-We Come Not to Praise Daimler, But to Acknowledge It

USA Recht | 24. Februar 2012 — Yesterday I discussed the apparent inaction of MF Global’s Board of Directors, when the former Chief Risk Officer left the comp…

FCPA: OCEG Illustrated Series: Managing Corruption Risks

USA Recht | 31. März 2012 — How do you move off dead center? That was a question posed by my colleague Mary Jones in a recent guest blog post. She gave s…

Neues zu Compliance aus den USA

USA Recht | 18. September 2010 — Für einen Jeden wichtig und lesenswert, der sich mit Corporate Compliance im Unternehmen befasst: In a recent article published…

FCPA: The CCO and Crisis Management

USA Recht | 21. März 2012 — “What, Me Worry?” is one of my favorite all-time slogans. Anyone who grew up on the 60s or 70s recognizes this comes from Alf…

Was sollten FCPA Compliance Programme enthalten?

USA Recht | 1. Juli 2010 — Stichwortartige, hilfreiche Zusammenstellung (von Christopher J. Steskal, USA, Januar 2008, www.mondaq.com) als roter Faden, w…

Wolfsberg Anti-Corruption Guidance

NIETZER & HÄUSLER | 5. November 2011 — Hilfreich für eigene Gedanken derjenigen Mitarbeiter, die in einem Unternehmen mit dem Thema Korruptionsvermeidung befasst sind…